// App-Quantinova.ai

7556 : Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.

Researchers

Presenter

  • Jean-Marie Michot

Principal Investigators

  • Marie Maerevoet

  • Philippe Georges Aftimos

  • Sylvie Rottey

  • Christian Diego Rolfo

  • Fritz Offner

  • Luc Van Rompaey

  • Mahan Moshir

  • Hans de Haard

  • Karen Silence

  • Patrick Pauwels

  • Karen Zwaenepoel

  • Ahmad Awada

  • Dominique Bron

  • Vincent Ribrag

Medical Centers

  • Institut Gustave-Roussy, Villejuif, France

  • Centre Hospitalier Universitaire, Ottignies, France

  • Jules Bordet Institute, Bruxelles, Belgium

  • Ghent University Hospital, Heymans Institute of Pharmacology, Ghent, Belgium

  • Phase I - Early Clinical Trials Unit, Antwerp University Hospital, Edegem, Belgium

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • arGEN-X, Zwijnaarde, Belgium

  • arGEN-X, Zwijnaarde, Belgium

  • Antwerp Univ Hosp, Retie, Belgium

  • UZA, Antwerpen, Belgium

  • Jules Bordet Institute, Bruxelles, Belgium

  • Institute Jules Bordet, Brussels, Belgium

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • T-cell lymphoma

  • Solid malignancies

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • ARGX-110

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01813539

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved